UK group to drive "universal access" to prostate LDR (low-dose-rate) brachytherapy:
This article was originally published in Clinica
The UK National Health Service (NHS) has formally established a prostate brachytherapy advisory group to steer service development in this specialism. The group's main aim will be to "support universal access to low-dose-rate (LDR) brachytherapy in the UK", by: optimising the use of services within radiotherapy centres that currently perform the technique; helping to commission services not available locally; and promoting best practice and evidence-based approaches, sourced in the UK and internationally.
You may also be interested in...
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.